Abbott slips after cutting 2026 growth outlook amid nutrition spinoff
Abbott Laboratories ABT reported Q3 2026 revenue of $13.0B, up 14.5% YoY, beating estimates. However, it lowered its 2026 growth outlook due to a planned nutrition business spinoff. Nutrition and Diagnostics units performed well, while MedTech and Pharma segments underperformed. Adjusted EPS rose 9% YoY to $1.42, exceeding forecasts.
How this was made
The 30-second read
Why it matters
The guidance downgrade is likely to drive short‑term downside, though strong segment performance may limit the decline.
Market read
First‑time disclosure of a lower growth outlook for a large‑cap health‑care company, creating immediate trading relevance.
What to watch
Abbott's nutrition and diagnostics segments beat forecasts, which could cushion the impact if the market focuses on those positives.
Background
Abbott Laboratories released its Q3 2026 earnings, beating revenue estimates but lowered its full‑year growth outlook amid a planned nutrition spinoff.
Ticker impact
Abbott reported Q3 2026 results and cut its full-year comparable sales growth outlook to about 6% from 6.5%-7.5%, a fresh guidance downgrade.
downward pressure as investors price in weaker outlook
The new lower growth target is material for a large-cap med‑tech company and was disclosed for the first time.
Market effects
May weigh on broader health‑care and med‑tech stocks as growth expectations tighten.
U.S. markets could see modest pullback in health‑care indices.
Limited to investors tracking large‑cap U.S. health‑care exposure.
Counterpoint
Some investors may view the cut as temporary and could see buying opportunity if the stock overreacts.
Key entities
- CompanyAbbott Laboratories
U.S. listed med‑tech and diagnostics firm (ticker ABT).